Sept 12 (Reuters) - MBX Biosciences, which is developing
peptide therapies for treating endocrine and metabolic
disorders, including diabetes and obesity, said on Thursday it
has raised $163.2 million in its U.S. initial public offering.
The biotechnology company priced its offering of 10.2
million shares at $16 apiece, at the high-end of its targeted
range of $14 to $16 each.